Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A comprehensive review integrating evidence from trials and biomarker studies to propose a precision immunotherapy framework for TNBC, addressing current standards and unresolved clinical challenges.
Mechanistic preclinical study with in vitro and mouse models showing ciprofol induces ferroptosis and enhances anti-PD-1 efficacy in HCC; no human clinical data or phase 1 trial reported, limiting evidence strength despite sound experimental design.
Mechanistic study in cell lines and mouse xenografts with a single candidate agent; no human data, no comparator arm, and no clinical endpoints reported.
This is a comprehensive narrative review synthesizing mechanistic and preclinical findings on deubiquitinases in breast cancer, with no clinical trial data, prospective validation, or regulatory approval to support practice change.
A scoping review synthesizing preclinical and mechanistic evidence on Sp1 in OSCC with scRNA-seq analysis, raising translational questions but reporting no clinical trials or human efficacy data.
This is a narrative review summarizing preclinical mechanistic evidence and emerging concepts about ferroptosis in pediatric cancer, without reporting original clinical trial data, efficacy comparisons, or definitive human outcomes.
A retrospective derivation and validation study identifying a three-gene prognostic score in ccRCC with independent association to overall survival; sound design but limited by retrospective nature, single-center derivation cohort, and lack of prospective validation.
Experimental validation in cell lines and a single syngeneic mouse model of a candidate target, lacking human efficacy data, phase 1 trial, or clinical translation to support practice change.